Gorlin Syndrome: Multiple Basal Cell Carcinomas

Gorlin syndrome, also termed nevoid basal cell carcinoma syndrome (NBCCS), represents an autosomal dominant hereditary disorder predisposing to multiple basal cell carcinomas, odontogenic keratocysts, and other malignancies. Affected individuals carry mutations in the PTCH1 (patched) tumor suppressor gene encoding protein component of hedgehog signaling pathway. Approximately 10% to 15% of Gorlin syndrome patients develop hundreds of basal cell carcinomas over lifetime, creating substantial morbidity through cumulative treatment burden and scarring. The syndrome also predisposes to multiple extracutaneous malignancies including medulloblastoma, ovarian cancer, and fibrosarcoma.

Genetics and Molecular Pathophysiology

PTCH1 gene mutations disrupt hedgehog pathway regulation, leading to constitutive pathway signaling and aberrant cell proliferation. The hedgehog pathway normally controls cell differentiation and proliferation; PTCH1 protein functions as receptor inhibitor, preventing pathway activation. Loss of PTCH1 function removes this brake, resulting in continuous hedgehog signaling within keratinocytes. This explains both elevated basal cell carcinoma propensity and numerous other developmental abnormalities associated with the syndrome.

Approximately 80% of Gorlin syndrome patients carry identifiable PTCH1 mutations. De novo mutations account for 20% to 30% of cases, occurring spontaneously without family history. Genetic testing identifies PTCH1 mutations with 90% sensitivity in clinically affected individuals. Genetic counseling proves important for affected families, as autosomal dominant inheritance means 50% of offspring will inherit the mutation.

Clinical Features and Diagnostic Criteria

Cutaneous Manifestations: Multiple basal cell carcinomas represent the hallmark feature. Gorlin syndrome patients typically develop first BCC in second to third decade of life, with hundreds accumulating by age 50 to 60. Some patients develop over 1000 BCCs during lifetime. The early age of onset distinguishes Gorlin syndrome from sporadic BCC development. Palmar/plantar pits (small depressions in palms and soles) occur in 70% to 85% of Gorlin patients and represent pathognomonic feature.

Skeletal Manifestations: Jaw abnormalities including micrognathia (small jaw), frontal bossing, and prognatism occur frequently. Odontogenic keratocysts develop in 75% to 90% of Gorlin patients, typically manifesting in second to third decade. These cysts are benign but may be aggressive, necessitating surgical management. Multiple jaw cysts create significant dental morbidity.

Extracutaneous Manifestations: Medulloblastoma occurs in 5% to 10% of Gorlin patients, typically developing before age 10. Early tumor surveillance in childhood proves essential. Ovarian fibromas occur in 20% of female patients, usually asymptomatic but requiring imaging surveillance. Cardiac fibromas, while rare (less than 5%), may cause arrhythmia or cardiac dysfunction. Other tumors including desmoplastic fibromas, mesenteric cysts, and pancreatic cysts occur less frequently.

Diagnostic Criteria: Diagnosis requires major criterion (multiple BCCs or odontogenic keratocyst) plus two or more minor criteria including palmar pits, frontal bossing, cleft palate, bifid ribs, or family history. Genetic testing may confirm PTCH1 mutations in diagnostic cases.

Malignancy Risks and Surveillance

The cumulative burden of malignancies in Gorlin syndrome significantly impacts quality of life and requires systematic surveillance. Basal cell carcinoma develops in virtually 100% of patients by adulthood, though penetrance and age of onset vary. Medulloblastoma, while less common, carries significant mortality risk if undetected; routine neuroimaging in childhood (typically MRI at age 3 to 5 years and periodic surveillance) identifies tumors amenable to treatment.

Ovarian fibromas in female patients require pelvic ultrasound surveillance in adulthood. While fibromas themselves remain benign, they may degenerate or rarely undergo malignant transformation. Cardiac surveillance through echocardiography identifies cardiac fibromas in asymptomatic individuals, allowing arrhythmia management or surgical intervention as needed.

Basal Cell Carcinoma Management in Gorlin Syndrome

Individual Lesion Treatment: Each BCC warrants appropriate treatment, though the sheer number necessitates practical strategies. Mohs micrographic surgery provides optimal outcomes for accessible lesions, achieving highest cure rates with minimal tissue sacrifice. For numerous lesions, standard surgical excision with adequate margins provides reasonable balance between cure rates and treatment burden. Smaller, accessible lesions may be managed with cryotherapy or topical approaches.

Field-Directed Preventive Therapy: Rather than treating each lesion individually, field-directed approaches address widespread dysplasia. Topical 5-fluorouracil or imiquimod applied to entire sun-exposed areas reduces new BCC development. Photodynamic therapy provides field treatment option. These approaches reduce future BCC burden compared to lesion-by-lesion treatment alone.

Systemic Hedgehog Pathway Inhibitors: Vismodegib and sonidegib, hedgehog pathway inhibitors, reduce new BCC development in Gorlin syndrome patients. Vismodegib (150 milligrams daily) demonstrates 50% to 75% reduction in new BCC development compared to baseline rates. Response is durable while treatment continues, with rapid increase in new lesions upon discontinuation. Sonidegib shows similar benefits. Side effects including muscle cramps, dysgeusia, and alopecia limit long-term tolerability in some patients.

HPI therapy proves particularly valuable for Gorlin syndrome patients with severe disease or those declining further surgical treatment. The ability to suppress new BCC development systemically alleviates burden of repeated excisions and scarring. Combination approaches using intermittent HPI therapy with topical field-directed treatment optimize outcomes while managing side effects.

Preventive Strategies and Comprehensive Management

Photoprotection: Aggressive sunscreen use (SPF 30+), protective clothing, and avoidance of peak sun exposure remain essential, though Gorlin patients develop BCCs even with rigorous sun protection due to genetic predisposition. Nevertheless, photoprotection minimizes additional non-genetic carcinogen exposure.

Dermatologic Surveillance: Regular comprehensive skin examinations (every 3 to 6 months) identify new BCCs early while lesions remain small and manageable. Clinical photography documents baseline lesions for comparison during subsequent visits. Patient education regarding self-examination facilitates early detection between professional visits.

Multidisciplinary Care: Gorlin syndrome management requires coordination among dermatologists, otolaryngologists, oral surgeons, orthopedic surgeons (for jaw management), and oncologists. Neurologic and cardiac surveillance specialists participate in comprehensive evaluation. Genetic counseling provides information regarding inheritance patterns and reproductive options.

FAQ

Will I definitely develop basal cell carcinoma if I have Gorlin syndrome?

Yes. Nearly 100% of Gorlin syndrome patients develop basal cell carcinoma during adulthood, though age of onset and number of lesions vary. First BCC typically develops in second or third decade. The number of BCCs develops over years to decades, requiring ongoing surveillance and management throughout life.

Can vismodegib prevent new basal cell carcinomas in Gorlin syndrome?

Yes. Vismodegib and sonidegib reduce new BCC development by 50% to 75% compared to baseline rates in Gorlin syndrome patients. However, treatment must continue indefinitely, as new lesions rapidly develop upon medication discontinuation. Side effects including muscle cramps and taste changes may limit long-term tolerability in some patients.

What is the dose of vismodegib used in Gorlin syndrome?

Standard vismodegib dosing is 150 milligrams orally daily. Treatment continues indefinitely with monitoring for efficacy and side effects. Blood work and physical examination at regular intervals (typically every 2 to 3 months) assess tolerability and disease response.

Does Gorlin syndrome increase risk of other cancers besides basal cell carcinoma?

Yes. Gorlin syndrome predisposes to medulloblastoma (5% to 10% of patients), ovarian cancer, cardiac tumors, and other malignancies. However, basal cell carcinoma remains by far the most common malignancy, occurring in virtually all patients. Surveillance for other tumors through imaging and clinical assessment is essential, particularly medulloblastoma screening in childhood.

References

1. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet Journal of Rare Diseases. 2008;3(1):32. Comprehensive syndrome overview and natural history.

2. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. Journal of Medical Genetics. 1993;30(6):460-464. Epidemiology of syndromic manifestations.

3. Bale AE, Yu KP. The hedgehog pathway and cancer. Journal of Pathology. 2001;193(4):427-432. Molecular pathophysiology of PTCH1 mutations.

4. Jones EA, Callen JP, Whittaker S, et al. Management of basal cell carcinoma in Gorlin syndrome: role of hedgehog pathway inhibitors. British Journal of Dermatology. 2013;168(1):149-151. Contemporary treatment approach overview.

5. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. New England Journal of Medicine. 2012;366(23):2171-2179. Clinical trial data for vismodegib in advanced BCC including syndromic patients.

6. Dummer R, Guminski A, Gutzmer R, et al. The 12-week, randomized, double-blind, placebo-controlled vismodegib study group. Journal of Clinical Oncology. 2016;34(14):1617-1625. Long-term efficacy data for HPI therapy.

7. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. American Journal of Medical Genetics. 1997;69(3):299-308. Comprehensive clinical characterization series.

8. Manassa EH, Buettner PG, Brettingham-Moore KH, et al. Second malignant neoplasms in naevoid basal cell carcinoma syndrome. British Journal of Cancer. 2004;91(2):257-261. Extracutaneous malignancy risks.

9. North JP, Golovato J, Urlacher L, et al. Atypical moles and malignant melanoma in Gorlin syndrome. Archives of Dermatology. 2012;148(3):321-325. Melanoma risk in syndromic patients.

10. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicology and Applied Pharmacology. 2007;224(3):287-291. Emerging targeted therapy mechanisms.